Agilex Biolabs has announced the appointment of Stephen McIntyre as its new Chief Executive Officer.
Agilex Biolabs is Australia’s largest regulated bioanalytical and toxicology laboratory. It is a member of the Healius network.
Mr McIntyre has extensive experience in executive leadership, transformational expansions and enabling Australian companies to establish and refine their global reach in the pathology and healthcare sectors.
"His background working in complex and highly regulated markets, both in Australia and globally, paired with a strong track record for facilitating successful mergers and acquisitions, makes him uniquely qualified to lead Agilex towards continued growth and success," said the company in a statement.
Mr McIntyre said, “Agilex has firmly established itself as the leading bioanalytical lab in Australia through its breadth of expertise, international reputation for quality, and unwavering dedication to scientific integrity. I’m thrilled to have the opportunity to guide the company’s maturation within the global biopharmaceutical industry.”
He continued, “I am grateful to the leadership Jason Valentine has provided in elevating Agilex to become the company it is today. It was under his watch that Agilex has achieved exponential growth, especially with the recent opening of Australia’s largest toxicology facility in Brisbane and Australia’s first satellite bioanalytical lab in a Phase 1 clinical research unit where customers can get time-sensitive preparation techniques like PBMC isolation within minutes of sample collection. I look forward to building Agilex’s future together alongside an outstanding executive team.”
Jason Valentine will remain in an executive leadership role as the company's chief operating officer. He is an original founding member of the company.
“With Stephen at the helm, we are about to embark on a pivotal chapter to the Agilex story,” he said. “His broad background and long list of successes is well-suited to help the Agilex team reach the next level so we can support more biopharma companies around the world as they advance tomorrow’s life-changing therapeutics.”